Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.26 EUR
Change Today -0.006 / -2.22%
Volume 0.0
LYF On Other Exchanges
As of 2:08 AM 10/13/15 All times are local (Market data is delayed by at least 15 minutes).

ekf diagnostics holdings plc (LYF) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/21/14 - €0.36
52 Week Low
01/20/15 - €0.24
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

ekf diagnostics holdings plc (LYF) Related Businessweek News

No Related Businessweek News Found

ekf diagnostics holdings plc (LYF) Details

EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East and Africa, and internationally. It offers glycated hemoglobin (HbA1c) analyzers, such as Quo-Test, Quo-Lab, and Biosen HbA1c analyzers for monitoring diabetes. The company also provides hemoglobin analyzers, including Hemo Control, a hemoglobin analyzer that provides quantitative lab quality results within 25 seconds for blood banks, hospitals, and clinics; Hemo Vet for veterinary use; STAT-Site, a hand-held hemoglobin analyzer; UltraCrit, a hematocrit measurement device for blood donor screening; HemataSTAT, a microhematocrit system, which offers quantitative hematocrit; and DiaSpect Hemoglobin T and DiaSpect Tm, the hemoglobin measurement systems. In addition, it offers glucose analyzers, such as C-Line GP+, C-Line Clinic, and S-Line Lab+ used in laboratories and sports institutions; and lactate analyzers comprising Biosen C-Line and S-Line glucose and lactate analyzers, as well as Lactate Scout+, a blood lactate analyzer for athletes, coaches, amateurs, and sport scientists. Further, the company provides rapid testing services, including pregnancy tests, such as True20 and QuPID for urine only or urine and serum pregnancy testing; and infectious diseases tests, such as H. Pylori, RELY Mono, RELY, and Strep A for the detection of pathonogenic micro-organisms, such as bacteria, parasites, viruses, and fungi. Additionally, it offers Sepsis testing services; clinical chemistry reagents; and diagnostic biomarker-based enzyme-linked immunosorbent assay kits and rapid tests, as well as maternal and women health diagnostic solutions. The company sells its products to GP surgeries, pharmacies, blood banks, sports clinics, hospitals, and laboratories through a network of distributors. EKF Diagnostics Holdings plc was founded in 1990 and is headquartered in Cardiff, the United Kingdom.

395 Employees
Last Reported Date: 03/16/15
Founded in 1990

ekf diagnostics holdings plc (LYF) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 238.0K GBP
Executive Chairman
Total Annual Compensation: 45.0K GBP
Chief Financial Officer, Finance Director, Se...
Total Annual Compensation: 167.0K GBP
Chief Operating Officer and Executive Directo...
Total Annual Compensation: 184.0K GBP
Chief Technology Officer and Executive Direct...
Total Annual Compensation: 182.0K GBP
Compensation as of Fiscal Year 2014.

ekf diagnostics holdings plc (LYF) Key Developments

EKF Diagnostics Holdings plc Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2015; Provides Net Debt Guidance for the Second Half of the Year 2015

EKF Diagnostics Holdings plc reported unaudited consolidated earnings results for the six months ended June 30, 2015. For the period, the company reported revenue of £16,781,000 compared with £16,766,000 for the same period last year. Operating profit was £6,331,000 compared with operating loss of £1,872,000 for the same period last year. EBITDA before exceptional items and share-based payment was £728,000 compared with £2,216,000 for the same period last year. Profit before income tax was £5,090,000 compared with loss before income tax of £2,468,000 for the same period last year. Profit attributable to owners of the parent was £5,165,000 or 1.20 pence diluted per share compared with loss attributable to owners of the parent of £2,718,000 or 0.81 pence diluted per share for the same period last year. Net cash used in operating activities was £2,090,000 compared with £3,317,000 for the same period last year. Purchase of property, plant and equipment was £1,181,000 compared with £898,000 for the same period last year. Purchase of intangibles was £2,628,000 compared to £702,000 for the same period last year. Adjusted EBITDA was £728,000 compared to £2,216,000 for the same period last year. The unaudited net debt position was £5.0 million compared to net cash of £2.1 million as of 31 Dec. 2014. The net debt position is expected to improve in the second half of the year following tender wins and with continuing payments being made by Mexican debtors.

Strategic Review Of Point-Of-Care Business Results In Another Proposal

Further to EKF Diagnostics Holdings plc's (AIM:EKF) announcements dated August, 18, 2015, EKF Diagnostics announces that it has now received a second non-binding preliminary proposal from an unrelated third party to offer $115 million - $125 million in cash for its Point-of-Care business (which excludes the Clinical Chemistry and Molecular Diagnostics businesses). The strategic review previously resulted inter-alia in a non-binding preliminary proposal of $110 million, on a cash free debt free basis, for our Point-of-Care business.

EKF Diagnostics Holdings plc Provides Earnings Guidance for the Six Months Ended June 30, 2015

EKF Diagnostics Holdings plc expected its results for the first half of 2015 to show unaudited revenues of £16.8 million, around the same level as last year, despite not having materially benefited from any tender wins in the current period. Unaudited adjusted EBITDA for the period will be around £0.7 million (in the first half of 2014: £2.2 million). This reduced level of earnings reflects the continuing impact of the investment in its Molecular division.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LYF:GR €0.26 EUR -0.006

LYF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LYF.
View Industry Companies

Industry Analysis


Industry Average

Valuation LYF Industry Range
Price/Earnings 40.6x
Price/Sales 2.2x
Price/Book 1.0x
Price/Cash Flow 14.0x
TEV/Sales 2.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EKF DIAGNOSTICS HOLDINGS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at